{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:50Z","timestamp":1791618950627,"version":"4.3.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.nmd.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:06:14Z","timestamp":1688504774000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Chiara","family":"Pisciotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-765X","authenticated-orcid":false,"given":"Davide","family":"Pareyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2023.07.001_bib0001","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(09)70108-5","article-title":"Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double blind, placebo-controlled, safety and efficacy trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaneurol.2013.3178","article-title":"High dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial","volume":"70","author":"Lewis","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","article-title":"Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial","volume":"10","author":"Pareyson","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0004","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1741-7015-7-70","article-title":"Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial","volume":"7","author":"Verhamme","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/brainsci11111447","article-title":"Challenges in treating charcot-marie-tooth disease and related neuropathies: current management and future perspectives","volume":"11","author":"Pisciotta","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.nmd.2023.07.001_bib0006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.mt.6300394","article-title":"Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells","volume":"16","author":"Hargrove","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2023.07.001_bib0007","doi-asserted-by":"crossref","first-page":"23358","DOI":"10.1038\/s41598-021-02694-1","article-title":"Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery","volume":"11","author":"Kagiava","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2023.07.001_bib0008","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.neuron.2022.05.003","article-title":"Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems","volume":"110","author":"Chen","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.nmd.2023.07.001_bib0009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nbd.2017.01.006","article-title":"Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo","volume":"100","author":"Lee","year":"2017","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nmd.2023.07.001_bib0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI96499","article-title":"PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2023.07.001_bib0011","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41467-021-22593-3","article-title":"AAV2\/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1A","volume":"12","author":"Gautier","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2023.07.001_bib0012","first-page":"130","article-title":"Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice","volume":"48","author":"Lee","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nmd.2023.07.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146533","article-title":"Gene therapy to promote regeneration in Charcot-Marie-Tooth disease","volume":"1727","author":"Sahenk","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.nmd.2023.07.001_bib0014","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s42003-021-01839-2","article-title":"Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1A","volume":"4","author":"Boutary","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jns.12543","article-title":"Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route toward translation","volume":"28","author":"Stavrou","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.nmd.2023.07.001_bib0016","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/hmg\/ddz199","article-title":"Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X","volume":"28","author":"Kagiava","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2023.07.001_bib0017","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/brain\/awz064","article-title":"Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy","volume":"142","author":"Schiza","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2023.07.001_bib0018","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0019","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40265-023-01836-1","article-title":"Mitigating serious adverse events in gene therapy with AAV vectors: vector dose and immunosuppression","volume":"83","author":"Ertl","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2023.07.001_bib0020","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.nmd.2023.07.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105332","article-title":"Adeno-associated virus (AAV)-based gene therapy products: what are toxicity studies in non-human primates showing us?","volume":"138","author":"Baldrick","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0022","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5607\/en.2019.28.2.279","article-title":"miR-381 attenuates peripheral neuropathic phenotype caused by overexpression of PMP22","volume":"28","author":"Lee","year":"2019","journal-title":"Exp Neurobiol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2023.07.001_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.nmd.2023.07.001_bib0027","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1172\/JCI130600","article-title":"Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models","volume":"129","author":"Morelli","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2023.07.001_bib0028","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI124194","article-title":"Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model","volume":"129","author":"Zhou","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2023.07.001_bib0029","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.24441","article-title":"Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease","volume":"78","author":"Sargiannidou","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0030","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/hmg\/ddy056","article-title":"Intrathecal gene therapy in mouse models expressing CMT1X mutations","volume":"27","author":"Kagiava","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2023.07.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137159","article-title":"AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model","volume":"131","author":"Presa","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2023.07.001_bib0032","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of intrathecal AAV9 gene therapy for giant axonal neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2023.07.001_bib0033","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1212\/01.WNL.0000171978.70849.c5","article-title":"NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients","volume":"65","author":"Sahenk","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.07.001_bib0034","doi-asserted-by":"crossref","first-page":"fcab252","DOI":"10.1093\/braincomms\/fcab252","article-title":"AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in Gars(P278KY\/+) mice","volume":"3","author":"Ozes","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.nmd.2023.07.001_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41434-021-00231-3","article-title":"AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1","volume":"29","author":"Ozes","year":"2022","journal-title":"Gene Ther"},{"key":"10.1016\/j.nmd.2023.07.001_bib0036","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/nm957","article-title":"Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)","volume":"9","author":"Sereda","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0037","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/jnr.24679","article-title":"Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats","volume":"98","author":"Prukop","year":"2020","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.nmd.2023.07.001_bib0038","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","article-title":"An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A","volume":"9","author":"Attarian","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.07.001_bib0039","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","article-title":"A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A","volume":"16","author":"Attarian","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2023.07.001_bib0040","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/ene.12783","article-title":"Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease","volume":"22","author":"Piscosquito","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0041","doi-asserted-by":"crossref","first-page":"23146","DOI":"10.1074\/jbc.M109.027128","article-title":"P2\u00d77-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy","volume":"284","author":"Nobbio","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2023.07.001_bib0042","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nbd.2016.07.017","article-title":"Tolerability and efficacy study of P2\u00d77 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy","volume":"95","author":"Sociali","year":"2016","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.nmd.2023.07.001_bib0043","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1038\/s41467-018-05420-0","article-title":"Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy","volume":"9","author":"Fledrich","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2023.07.001_bib0044","doi-asserted-by":"crossref","first-page":"e2356","DOI":"10.1212\/WNL.0000000000200325","article-title":"Randomized phase 2 study of ACE-083 in patients with Charcot-Marie-Tooth disease","volume":"98","author":"Thomas","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.07.001_bib0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/497541","article-title":"Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants","volume":"77","author":"Khajavi","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2023.07.001_bib0046","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1093\/brain\/aws299","article-title":"Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice","volume":"135","author":"Patzk\u00f3","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2023.07.001_bib0047","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1086\/519926","article-title":"Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy","volume":"81","author":"Khajavi","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2023.07.001_bib0048","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.freeradbiomed.2020.09.019","article-title":"Curcumin-cyclodextrin\/cellulose nanocrystals improve the phenotype of Charcot-Marie-Tooth-1A transgenic rats through the reduction of oxidative stress","volume":"161","author":"Caillaud","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0049","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1007\/s12035-022-02838-y","article-title":"Treatment with IFB-088 improves neuropathy in CMT1A and CMT1B Mice","volume":"59","author":"Bai","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0050","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1126\/science.abb3356","article-title":"tRNA overexpression rescues peripheral neuropathy caused by mutations in tRNA synthetase","volume":"373","author":"Zuko","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.nmd.2023.07.001_bib0051","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.abb3414","article-title":"The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy","volume":"373","author":"Spaulding","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.nmd.2023.07.001_bib0052","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.3664","article-title":"Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A","volume":"20","author":"Fledrich","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0053","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.15252\/emmm.201606349","article-title":"Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination","volume":"8","author":"Bolino","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0054","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/brain\/awac402","article-title":"Imbalance of NRG1-ERBB2\/3 signalling underlies altered myelination in Charcot-Marie-Tooth disease 4H","volume":"146","author":"El-Bazzal","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2023.07.001_bib0055","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1523\/JNEUROSCI.3427-15.2016","article-title":"Cell-surface and secreted isoforms of CSF-1 exert opposing roles in macrophage-mediated neural damage in Cx32-Deficient Mice","volume":"36","author":"Groh","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/j.nmd.2023.07.001_bib0056","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/glia.24158","article-title":"Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot-Marie-Tooth 1A","volume":"70","author":"Klein","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.nmd.2023.07.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114195","article-title":"Presymptomatic macrophage targeting has a long-lasting therapeutic effect on treatment termination in a mouse model of Charcot-Marie-Tooth 1","volume":"357","author":"Ostertag","year":"2022","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0058","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/jnnp-2015-310835","article-title":"Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses","volume":"87","author":"Rajabally","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2023.07.001_bib0059","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.nmd.2009.01.006","article-title":"The phenotype of Charcot-Marie-Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy","volume":"19","author":"Houlden","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.07.001_bib0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2013.01.010","article-title":"Rapidly progressive asymmetrical weakness in Charcot-Marie-Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy","volume":"23","author":"Cottenie","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2023.07.001_bib0061","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.25198","article-title":"Myelin abnormality in Charcot-Marie-Tooth type 4J recapitulates features of acquired demyelination","volume":"83","author":"Hu","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0062","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jocn.2020.03.014","article-title":"Immune-mediated inflammatory polyneuropathy overlapping Charcot-Marie-Tooth 1B","volume":"75","author":"Escorcio-Bezerra","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2023.07.001_bib0063","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2016.08.019","article-title":"An oral NaV1.8 blocker improves motor function in mice completely deficient of myelin protein P0","volume":"632","author":"Rosberg","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nmd.2023.07.001_bib0064","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/brain\/123.7.1516","article-title":"Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A","volume":"123","author":"Krajewski","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2023.07.001_bib0065","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nm.2396","article-title":"HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease","volume":"17","author":"d'Ydewalle","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0066","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/brain\/awx375","article-title":"HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease","volume":"141","author":"Benoy","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2023.07.001_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113281","article-title":"HDAC6 inhibition promotes \u03b1-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice","volume":"328","author":"Picci","year":"2020","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0068","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1111\/bph.15231","article-title":"A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A","volume":"177","author":"Ha","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0069","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1084\/jem.20181040","article-title":"Gene therapy targeting SARM1 blocks pathological axon degeneration in mice","volume":"216","author":"Geisler","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2023.07.001_bib0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/acn3.51523","article-title":"TRPV4 mutations causing mixed neuropathy and skeletal phenotypes result in severe gain of function","volume":"9","author":"Taga","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0071","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2009469118","article-title":"Dysregulation of myelin synthesis and actomyosin function underlies aberrant myelin in CMT4B1 neuropathy","volume":"118","author":"Guerrero-Valero","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2023.07.001_bib0072","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1212\/WNL.0000000000006811","article-title":"Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1","volume":"92","author":"Fridman","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.07.001_bib0073","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/jnnp-2018-320198","article-title":"Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in hereditary sensory neuropathy type 1","volume":"90","author":"Kugathasan","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2023.07.001_bib0074","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41588-020-0615-4","article-title":"Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes","volume":"52","author":"Cortese","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.nmd.2023.07.001_bib0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164954","article-title":"Sorbitol reduction via AT-007 (govorestat) ameliorates synaptic dysfunction and neurodegeneration in models of sorbitol dehydrogenase deficiency","volume":"8","author":"Zhu","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.nmd.2023.07.001_bib0076","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1007\/s00415-023-11643-z","article-title":"Neuromuscular junction involvement in inherited motor neuropathies: genetic heterogeneity and effect of oral salbutamol treatment","volume":"270","author":"McMacken","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2023.07.001_bib0077","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/jnnp-2019-320717","article-title":"Expanding the spectrum of genes responsible for hereditary motor neuropathies","volume":"90","author":"Previtali","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2023.07.001_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146625","article-title":"Are we prepared for clinical trials in Charcot-Marie-Tooth disease?","volume":"1729","author":"Rossor","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.nmd.2023.07.001_bib0079","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26633","article-title":"Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints","author":"Reilly","year":"2023","journal-title":"Ann Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:54Z","timestamp":1760775234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0960896623001694"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.07.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}